# A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants

> **NCT06491550** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 91 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** AZD4144- Part A
- **DRUG:** Placebo- Part A
- **DRUG:** AZD4144- Part B
- **DRUG:** Placebo- Part B
- **DRUG:** Rosuvastatin and Furosemide- Part C
- **DRUG:** Rosuvastatin, Furosemide, and AZD4144 Part C

## Key facts

- **NCT ID:** NCT06491550
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-15
- **Primary completion:** 2025-06-11
- **Final completion:** 2025-06-11
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2025-07-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06491550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06491550, "A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06491550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*